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IgG4-relateddisease(IgG4-RD)isamultiorganinﬂammatorydiseaseinwhichdiverseorganmanifestationsarelinkedbycommon
histopathological and immunohistochemical features. Prospective studies of IgG4-RD patients are required to clarify the natural
history,long-termprognosis,andtreatmentapproachesinthisrecentlyrecognizedcondition.PatientswithIgG4-RDhavediﬀerent
organ manifestations and are followed by multiple specialties. Divergent approaches to the assessment of patients can complicate
the interpretation of studies, emphasizing the critical need for validated outcome measures, particularly assessments of disease
activity and response to treatment. We developed a prototype IgG4-RD Responder Index (IgG4-RD RI) based on the approach
used in the development of the Birmingham Vasculitis Activity Score for Wegener’s granulomatosis (BVAS/WG). The IgG4-RD RI
was reﬁned by members of the International IgG4-RD Symposium Organizing Committee in a paper case exercise. The revised
instrument was applied retrospectively to ﬁfteen IgG4-RD patients at our institution. Those scores were compared to physician’s
global assessment scale for the same visits. This paper describes the philosophy and goals of the IgG4-RD RI, the steps in the
development of this instrument to date, and future plans for validation of this instrument as an outcome measure.
1.Introduction
Measurement of disease activity is critical for longitudinal
assessments in both observational studies and clinical trials.
In the ﬁeld of rheumatology, more than 250 assessment tools
have been developed and validated to evaluate pathology,
symptoms, function, and health status of patients with
rheumatic diseases [1]. Such instruments should be com-
patible with regulatory requirements of the Food and Drug
Administration (FDA) and generally require prospective
studies for completion of the validation process [2].
IgG4-related disease (IgG4-RD) is an increasingly rec-
ognized immune-mediated disease that is characterized by
a lymphoplasmacytic inﬁltrate enriched with IgG4-positive
plasma cells and a distinctive storiform ﬁbrosis of aﬀected
organs[3].Commonly involved organsinclude thepancreas,
biliary tree, orbits, salivary glands, and retroperitoneum,
among many others. Organ involvement usually occurs in a
metachronousbutoverlappingfashion.TheserumIgG4level
is often but not always elevated [4]. Because of the novelty
of IgG4-RD, little eﬀort to date has been devoted to the
development of outcome measures for this newly recognized
condition.
A disease responder index is a tool designed to detect
any changes in disease activity and identify improvement
and worsening in the same and/or diﬀerent organ systems.
A responder index permits objective quantiﬁcation of the
treatmentresponsebyprovidingstandardizedoutcomemea-
sures. Assessing clinical response and not simply serologic
response is increasingly important to establish endpoints in
randomized control trials.
No randomized control trials have been conducted for
IgG4-RD treatment to date [5]. Management is based cur-
rently on small case series and observational studies. Glu-
cocorticoids are the standard ﬁrst-line treatment for IgG4-
RD and patients whose disease has not reached an advanced
stage of ﬁbrosis generally respond well to this treatment, at
least initially [5]. Recent data has shown that rituximab can
be used successfully to treat IgG4-RD [6].2 International Journal of Rheumatology
Two major features of IgG4-RD pose signiﬁcant chal-
lenges for the development of outcome measures. The ﬁrst
is the complex, multiorgan system nature of this disease,
which makes it diﬃcult to summarize the state of disease
activity across all organs. The second is the fact that the
stage of disease activity can diﬀer across organs, such that
a patient can have active inﬂammation likely to respond to
immunosuppressioninoneorganandadvancedﬁbrosis(less
likely to respond to treatment) in another.
We have developed an IgG4-RD responder index (IgG4-
RD RI) for use as an outcome measure in an ongoing pilot
trial of rituximab in this condition. We intend that this
instrument will measure not only disease activity but will
also incorporate features that capture the need for urgent
treatment and catalogue disease-related damage. This paper
is designed to provide information on the development
and implementation of the IgG4-RD RI. We report the
philosophy behind the development of the IgG4-RD RI
to date, the steps taken to create the instrument through
the enlistment of assistance of international experts in this
condition, and the plans for completion of the IgG4-RD RI
validation process.
2. Methods
2.1. Overview of the Instrument Development Approach. The
IgG4-RD RI was designed to assess disease activity from visit
to visit using clinician-generated assessments of both objec-
tive and subjective measures. The IgG4-RD RI uses a scoring
system from 0–4 for each organ system or site and asks the
clinician to rate the extent of disease activity and damage
at the time of the clinical encounter. The IgG4-RD RI was
revised by the Organizing Committee of the International
IgG4-related Disease Symposium, held in Boston in October,
2011 [http://www2.massgeneral.org/pathology/symposium/
IgG4 related systemic dis.asp]. This group was comprised
of 39 experts from 9 countries, with subspecialty exper-
tise in rheumatology, gastroenterology, allergy/immunology,
nephrology, surgery, pathology, and radiology. Further revi-
sionsweremadefollowingasimulationexerciseinvolvingsix
paper case descriptions of real patients, completed by IgG4-
RD symposium participants. Finally, both the IgG4-RD RI
that emerged from these development steps and a physician
global assessment (PGA) were used to assess the disease
retrospectively in terms of disease activity and damage.
The Pearson’s correlation coeﬃcient was then calculated to
c o m p a r et h eI g G 4 - R DR Ia n dP G Ar e s p o n s e s .
2.2. Model Disease Activity Tool. The IgG4-RD RI was mod-
eled on the Birmingham Vasculitis Activity Score for
Wegener’s granulomatosis (BVAS/WG) [7]. The BVAS/WG is
a formally validated and widely used instrument for the
measurement of disease activity in granulomatosis with
polyangiitis (formerly Wegener’s granulomatosis) and mi-
croscopic polyangiitis, a pair of distinct but overlapping con-
ditions often termed antineutrophil cytoplasmic antibody
(ANCA)-associated vasculitides (AAVs) [8]. The BVAS/WG
is a clinician-scored instrument in which each disease
activity in each organ system is graded “persistent,” “worse,”
or “none” at each clinic visit. The number of items of
“persistent” or “worse” for each organ system is totaled
and used to quantify the states of disease ﬂare, persistent
disease, or remission. The BVAS/WG was selected because
of the experience of one of the authors (J. H. Stone) as
a lead developer of this instrument; similarities between
ANCA-associated vasculitis and IgG4-RD, including the
propensities for multi-organ system involvement; the broad
range of disease activity between ﬂare and remission; the
high frequency of disease-related damage (which must be
distinguished from active disease); the absence of reliable
biomarkersthatnecessitatesrelianceuponclinicalindicesfor
longitudinal assessments.
2.3. Scoring Sheet. The IgG4-RD RI, designed to emphasize
ease of use, includes speciﬁc reminders to consider activity
within all organs involved commonly in IgG4-RD (Figure 1).
The scoring rules appear in the ﬁrst box. At each visit,
physiciansenterascorefrom0–4foreachorgan/siteaﬀected,
indicating whether the organ/site is normal, improved, new
or recurrent, or worse on treatment. The physician also
provides yes/no answers for each organ site to the questions
of whether the disease is symptomatic; whether the disease
activity requires treatment urgently; whether the organ
dysfunction observed is related to damage rather than (or
in addition to) active disease. At the end of this table,
the serum IgG4 concentration in milligrams per deciliter
is entered along with a score of 0–4, indicating whether
the IgG4 concentration has improved, become newly or
recurrently elevated, or increased despite treatment since the
last visit. The scoring scheme for serum IgG4 concentration,
therefore, parallels the schemes for individual organ system
activity assessment. The cumulative glucocorticoid dose (in
prednisoneequivalents)sincethelastvisitandtotalIgG4-RD
RI score are then calculated.
2.4. Speciﬁc Interpretations of Individual Organ System Scores.
The numbers for each organ score refer to disease activity,
distinguished from organ dysfunction related to damage:
(i) “0” signiﬁes the absence of active disease in that
organ. A score of 0 is appropriate when the organ
system has never been aﬀected by active IgG4-RD,
or when previously evident disease within that organ
has resolved;
(ii) “1” indicates that disease activity within an organ has
improved but still persists to some degree;
(iii) “2” indicates that the disease within that organ has
remained persistent and unchanged since the last
visit;
(iv) “3” indicates the presence of new or recurrent disease
activity;
(v) “4” refers to disease that has worsened despite treat-
ment.
2.5.OrganSite. Theorgansiteswereselectedforinclusion in
the IgG4-RD RI based on a review of the existing literatureInternational Journal of Rheumatology 3
IgG4-RD responder index 
Descriptor Level  mg/dl Score
Serum IgG4 concentration 
Total activity score 
 ______  
Total number of urgent organs:  _______ 
Total number of damaged organs: _______ 
Activity Damage
Organ/site Organ/site 
score (0-4) 
Symptomatic
(Yes/No) 
Urgent 
(Yes/No) 
Present
(Yes/No) 
Pachymeninges 
Pituitary gland 
Orbits and lacrimal glands 
Salivary glands 
Thyroid
Lymph nodes 
Lungs 
Aorta and large blood vessels 
Retroperitoneum, mediastinum, and 
mesentery 
Pancreas 
Bile duct and liver 
Kidney
Skin 
Other sclerosis/mass formation 
Date form completed: (e.g., 7 / July / 2050) 
Scoring rules
Scoring refers to manifestations of disease activity present in the last 28 days
Scoring: 0       Normal or resolved 
1       Improved 
2       Persistent (unchanged from previous visit; still active) 
3       New / recurrence 
4       Worsened despite treatment 
Deﬁnitions
Organ/site score: the overall level of IgG4-RD activity within a speciﬁc organ system 
(presence of urgent disease within an organ leads to doubling of that organ system score)
Steroid dose at the time of assessment (prednisone equivalent): 
____ mg/day 
Cumulative steroid dose in the past 28 days:  
____ mg prednisone equivalent 
Organ/sites (×2 if urgent) + serum IgG4 score:
Symptomatic: is the disease manifestation in a particular organ system symptomatic? (
Urgent disease: disease that requires treatment immediately to prevent serious organ dysfunction (
Damage: organ dysfunction that has occurred as a result of IgG4-RD and is considered permanent (
Case number:
Y = yes; N = no)
Y = yes; N = no)
Y = yes; N = no)
Figure 1: IgG4-related Disease Responder Index (IgG4-RD RI) Scoring Sheet this is a sample sheet of the IgG4-RD RI on which physicians
score patient’s disease activity at a given clinic visit.
(Table 1)[ 3]. For ease of conceptualization, the sites of
potential organ involvement are listed from head to toe.
This structure is similar to that of the BVAS/WG scoring
sheet, on which disease activity is scored by organ system,
and each disease site is assigned a designation of normal,
persistent disease activity, and new/worse disease activity,
with numerical scores corresponding to each state [7]. Each
organ site has speciﬁc disease manifestations common to
IgG4-RD (the appendix). The IgG4-RD RI category of
“other” organ/site involvement is important because the4 International Journal of Rheumatology
Table 1: Diseases commonly associated with IgG4-related disease.
IgG4-related spectrum diseases
Idiopathic hypertrophic pachymeningitis
Orbital pseudotumor
Mikulicz’s disease
Kuttner’s tumor
Eosinophilic angiocentric ﬁbrosis
Riedel’s thyroiditis
Idiopathic cervical ﬁbrosis
Pulmonary inﬂammatory pseudotumor
Chronic sclerosing aortitis
Inﬂammatory abdominal aortitis
Autoimmune pancreatitis
Sclerosing cholangitis
Retroperitoneal ﬁbrosis
Inﬂammatory pseudotumor of the kidney
protean nature of this disease makes it impossible to capture
all potential sites of disease. In addition, we anticipate that
new clinical manifestations of this disease and possible even
new sites of organ involvement will be described as the
clinical phenotype of this disease is understood more fully.
2.6. Symptoms and Signs of IgG4-RD. Lists of the most
common symptoms and signs within a given organ system
are included in the IgG4-RD RI instructions (see the
appendix), principally as a reminder to the clinician of the
possible disease manifestations to consider when scoring
disease activity and damage. The physician simply denotes
on the form the presence or absence of symptoms for a given
IgG4-RD site. This feature of the instrument ensures that a
subjective measure is included. Good clinical judgment and
a thorough knowledge of the disease manifestations of this
condition are essential, as with any clinical responder index.
2.7. Urgency. Capturing the need for urgent treatment is an
important aspect of the IgG4-RD RI. Some disease mani-
festations of IgG4-RD require the immediate institution of
treatmenttopreventpermanentorgandamage.Forexample,
IgG4-related sclerosing cholangitis can lead to cirrhosis
within several months of diagnosis and requires the prompt
initiation of therapy. In contrast, the lymphadenopathy of
IgG4-RD remains unchanged for prolonged periods in many
patients and may never require treatment. The “urgent”
column in the IgG4-RD RI is designed to capture aspects of
the disease that require the immediate start of immunosup-
pression in order to preserve organ function.
The score for an organ site is doubled when the need
to initiate treatment for active IgG4-RD at a particular or
organ/site is considered urgent. For example, if a patient
has new IgG4-related sclerosing cholangitis, the total score
for that organ/site would be 6 instead of 3. Similarly, if the
patient’s biliary status has worsened despite therapy since the
time of the last visit and an urgent escalation of therapy is
required to treat the IgG4-related sclerosing cholangitis, then
that organ score would be 8 rather than 4. Only the score of
the individual organ site is doubled in this setting, not the
total IgG4-RD RI score.
2.8. Damage. The concept of damage is related directly to
that of disease activity. Consequently, the two concepts must
be considered in tandem. Organ damage results from active
diseaseandinsomecasesbothactivediseaseanddamagecan
be present in the same organ system simultaneously. In other
cases, organ dysfunction is related more to damage than to
active IgG4-RD. Immunosuppression must be targeted to
active IgG4-RD, not to damage resulting from previously
active therapy. The most appropriate use of immunosup-
pression is to control active disease and prevent disease-
related damage. It is particularly ideal to employ immuno-
suppression at a stage of disease when the histopathology is
characterized by a lymphoplasmacytic inﬁltrate rather than a
predominance of acellular ﬁbrosis [9].
The clinical assessment of damage can be challenging.
Radiographic studies such as computed tomography (CT)
and positron emission tomography with CT (PET-CT) can
aid the clinician in determining which organs have been
damaged. For example, even conceding that active disease
might be present simultaneously with damage within the
pancreas, the ﬁnding of atrophic changes by CT scan within
thatorganwouldbeconsideredtobetheresultofdamage.In
such a case, both active disease and disease-related damage
should be scored.
2.9. Serum IgG4 Concentration. Scoring also includes a con-
sideration of the serum concentration of IgG4. The serum
IgG4 level may become elevated in a patient experiencing an
active ﬂare [6, 10]. However, not every patient with IgG4-
RD has an elevated serum IgG4 level at baseline, even before
treatment. It is well established that classic IgG4-RD can be
active in the absence of elevated serum IgG4 concentrations.
The IgG4-RD serum level in the IgG4-RD RI is scored
accordingtonormal,improved,persistent,new,recurrent,or
worsened despite treatment. Patients with rising serum IgG4
levels would have higher scores indicating worsening disease
activity.
2.10. Total Scoring. The sum of the disease activity in all of
the organ sites plus the serum IgG4 concentration score (also
graded on a 0–4 scale) yields the total activity score. An
individual active organ site is doubled for urgency and added
to the other organ sites. This number can be compared
between visits to assess the disease activity over time as well
as being used for a clinical trial endpoint. The longitudinal
recording of damage, though not included in the overall
disease activity score, is essential to the formulation of the
patient’s overall outcome.
2.11.GlucocorticoidUse. Glucocorticoidsarethecornerstone
of IgG4-RD treatment, and most patients respond promptly
to this treatment, at least initially. Thus, careful recording
of the dose of prednisone (or prednisone equivalent) in theInternational Journal of Rheumatology 5
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Figure 2:SubspecialtiesofIgG4-RDRISimulationExercisePartici-
pants(n = 21)therewere21participantscompletingthesimulation
exercises and the pie chart represents the percentage breakdown for
each medical subspecialty.
interval between the current visit and the preceding one is
essential to a full understanding of the degree of disease
activity.
3. Results
3.1. Simulation Exercises. The IgG4-RD RI went through
several development stages and iterations before arriving at
its current format. A simulation exercise using paper case
descriptions of six real patients was sent to attendees of
the International IgG4-RD Symposium (held in Boston, MA,
USA October 2011). Participants were asked to score the
simulation exercises using the IgG4-RD RI. The participants
received written instructions on how to apply the IgG4-RD
RI but did not attend a training session (the appendix).
Twenty-one individuals participated in this exercise, provid-
ing valuable feedback from a cross-section of investigators
interested in IgG4-RD. The physicians who completed the
exercises included a variety of subspecialists, particularly
rheumatologists and pathologists (Figure 2).
The simulation exercises were presented as clinical
vignettes, including data from histories, physical examina-
tions, laboratory results, and radiologic ﬁndings for each
case. Accompanying each clinical vignette was at least one
clinical photograph, radiology study, or histologic image to
illustrate the case eﬀectively. The physicians then used all of
the information presented in the simulation exercise to com-
plete a separate IgG4-RD RI scoring sheet for each case. The
results were scored for each participant against standardized
answers prepared by consensus of the four authors.
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Figure 3: Correlation between physician global assessment (PGA)
and IgG4-RD RI the PGA and IgG4-RD RI were compared using
linear regression.
The purpose of this exercise was to solicit feedback
on the IgG4-RD RI from physicians who were experts in
the evaluation of patients with this disorder from diﬀerent
perspectives. Several common scoring errors were observed
in this exercise. These included scoring organ involvement in
which clinical symptoms and signs had resolved entirely as
improved but persistent (i.e., “1”) rather than resolved (i.e.,
“0”). Another scoring discrepancy resulted from incorrectly
scoring patients oﬀ treatment who were recurrent (“3”)
as if they were receiving treatment (“4”). A third error
was failing to double the organ/site score, when disease
requiring treatment urgently was present. Comments from
the participants in this exercise contributed substantially to
important revisions of the draft instrument. We reformatted
the scoring sheet in order to address the common scoring
diﬀerences from the simulation case exercises.
3.2. Retrospective Application of the IgG4-RD RI. The next
stepinthedevelopmentoftheIgG4-RDwastheretrospective
use of the instrument for ﬁfteen individual clinic and in-
patient evaluations among patients in the Massachusetts
GeneralHospitalIgG4-RDRegistry.Twoblindedrheumatol-
ogy experts scored an IgG4-RD patient visit using either the
IgG4-RDRIorthephysician’sglobalassessmentscale(PGA).
These results were then compared (Figure 3). The Pearson’s
correlation coeﬃcient was 0.93 (P<0.0001).
4. Discussion
As the ﬁeld of IgG4-RD is poised to move beyond the
descriptive phase of the disease, validated outcome measures
are required to advance the understanding of this condition
and the assessment of new treatment approaches. The cur-
rent iteration of the IgG4-RD RI marks an important step
toward the availability of useful outcome measures in this
disease. We anticipate that additional validation steps for
this instrument will be required, but this paper describes6 International Journal of Rheumatology
accurately the philosophy and goals behind the IgG4-RD RI.
Its methods and appendices will serve as important guidance
documents in the future.
The development eﬀorts to date have created a one-
pageinstrumentsupportedbytheinstructionmanualshown
in the appendix. Data included on this single page include
indications of disease activity across a full spectrum of
potential organ involvement; the serum IgG4 concentration;
assessments of the need for treatment on an urgent basis;
the recording of damage in organ systems; the sum of recent
glucocorticoid use. Expertise with the use of the IgG4-RD
RI may, therefore, become a concise and important tool for
clinical trials and other investigations related to this disorder.
Although the developers of the IgG4-RD RI have relied
signiﬁcantly upon the BVAS/WG in creating this instru-
ment, the IgG4-RD RI diﬀers in important ways from
the BVAS/WG. The “urgent” column in the IgG4-RD RI
highlights features of the disease that require the prompt
institution of treatment and is, therefore, analogous to the
“major” designations given to some organ system manifes-
tations in the BVAS/WG [7]. However, the BVAS/WG does
not record disease damage on the same page. Rather, clinical
trials in AAV have generally used a separate instrument, the
Vasculitis Damage Index [11], for this purpose. Although it
is critical that the concepts of disease activity and damage
be kept separate and recorded appropriately during clinical
assessments,itmaybeusefultohaveanindicationofdamage
on the same one-page case report form even if damage
does not contribute to the overall disease activity score. This
model matches more closely the decision-making process
that clinicians undertake on a daily basis in encounters
with patients: are the signs of organ dysfunction due to
active disease, or are they more accurately a reﬂection of
damage rather than a process that requires more intensive
immunosuppression?
The IgG4-RD RI will ﬁnd its greatest use in the research
setting, either in the context of clinical trials or in other
types of investigations that require the careful longitudinal
assessments of patients’ clinical status. Because consistency
of its application from visit to visit is critical, it will be
most useful to ensure whenever possible that the same
investigators complete the IgG4-RD RI for the same patient
across all visits.
Signiﬁcant debate now exists within the community of
IgG4-RD investigators about the utility of serum IgG4 con-
centration measurements in the diagnosis and management
of this disorder [12]. Inclusion of the serum IgG4 concentra-
tion in the IgG4-RD RI at this point permits an analysis of
the value of this measurement in the context of other organ
disease assessments. We hypothesize that further analysis of
these data will conﬁrm the utility of serial measurements,
at least in a subset of patients. This hypothesis, however,
requires conﬁrmation through studies of larger numbers of
patients in a variety of states of disease activity.
The simulation case exercises illustrated some shortcom-
ings in early iterations of the IgG4-RD RI that led to appro-
priaterevisionsoftheoriginalindex.Theexperiencewiththe
simulation exercise highlighted the importance of adequate
training with the instrument prior to its use in the research
setting. The IgG4-RD RI is simpler than many clinical assess-
ment tools for multiorgan diseases, but both a thorough
understanding of the clinical breadth of IgG4-RD itself and
a high degree of familiarity with the index are required in
order to employ it eﬀectively. We anticipate that a focused
period of instruction for investigators in the context of a
formal training course will be required before this tool can
be used in the context of a clinical trial.
In conclusion, progress in IgG4-RD will be contingent
upontheabilitytoassesspatientsrigorouslyinalongitudinal
manner, using validated outcome measures. The IgG4-RD
RI described in this paper represents a broad eﬀort at the
development of a disease activity and responder index that
can be employed in clinical trials and other investigations
of patients with this emerging immune-mediated condition.
The next steps in validation will include a multicenter study
of patients recruited from a core group of sites with extensive
experience in the diagnosis and management of this disease.
Appendix
For more information please refer to IgG4-RD RI Instruc-
tions Manual. (See Supplementary Material available online
at doi:10.1155/2012/259408.)
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